Quince Therapeutics

(NASDAQ) QNCX

Current Price$1.30

Market Cap$21.19M

Since IPO (2019)-100%

5 Year-100%

1 Year-88%

1 Month-20%

Quince Therapeutics Financials at a Glance

Market Cap

$21.19M

Revenue (TTM)

$0.00

Net Income (TTM)

$83.98M

EPS (TTM)

$-16.43

P/E Ratio

-0.08

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$1.30

Volume

9,670

Open

$1.23

Price

$1.30

Volume

9,670

Open

$1.23

Previous Close

$1.30

Daily Range

$1.21 - $1.31

52-Week Range

$0.80 - $45.50

Dividend

$0.00

Beta (Volatility)

1.23 (Average)

Price

$1.30

Volume

9,670

Open

$1.23

Previous Close

$1.30

Daily Range

$1.21 - $1.31

52-Week Range

$0.80 - $45.50

QNCX News

falling chart man watching computer screen

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

David HaenFeb 7, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quince Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Dirk Thye, MD

Website

quincetx.com

Headquarters

South San Francisco, CA 94080, US

QNCX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-248%

Return on Capital

-1%

Return on Assets

-90%

Earnings Yield

-12.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$21.19M

Shares Outstanding

16.30M

Volume

9.67K

Avg. Volume

10.49M

Financials (TTM)

Gross Profit

$142.00K

Operating Income

$50.43M

EBITDA

$50.29M

Operating Cash Flow

$41.42M

Capital Expenditure

$352.00K

Free Cash Flow

$41.78M

Cash & ST Invst.

$17.75M

Total Debt

$18.36M

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$39.00K

-143.8%

Gross Margin

0.00%

N/A

Market Cap

$21.19M

N/A

Market Cap/Employee

$588.64K

N/A

Employees

N/A

Net Income

$39.46M

-216.7%

EBITDA

$16.20M

-30.3%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$604.00K

-102.3%

Accounts Receivable

$3.62M

+310.7%

Inventory

$0.00

N/A

Long Term Debt

$330.00K

-97.8%

Short Term Debt

$18.03M

+18677.1%

Return on Assets

-89.80%

N/A

Return on Invested Capital

-1.00%

N/A

Free Cash Flow

$16.83M

-119.0%

Operating Cash Flow

$16.97M

-124.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MGXMetagenomi, Inc. Common Stock

MGXMetagenomi, Inc. Common Stock$1.42-0.70%

GUTSFractyl Health, Inc. Common Stock

GUTSFractyl Health, Inc. Common Stock$0.75+1.75%

ATYRaTyr Pharma, Inc.

ATYRaTyr Pharma, Inc.$0.92-11.18%

CAMPCAMP4 Therapeutics Corporation

CAMPCAMP4 Therapeutics Corporation$4.34+6.90%

DTILPrecision BioSciences, Inc.

DTILPrecision BioSciences, Inc.$7.48-0.53%

ADVMAdverum Biotechnologies, Inc.

ADVMAdverum Biotechnologies, Inc.$4.36+0.00%

KLRSKalaris Therapeutics Inc

KLRSKalaris Therapeutics Inc$5.15+1.78%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.47+0.07%

IRENIren

IRENIren$56.85-0.07%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.34-0.00%

FLNCFluence Energy

FLNCFluence Energy$18.97+0.40%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$45.73+0.00%

SOFISoFi Technologies

SOFISoFi Technologies$16.00-0.02%

ONDSOndas

ONDSOndas$8.89-0.05%

Questions About QNCX

What is the current price of Quince Therapeutics?

Quince Therapeutics is trading at $1.30 per share.

What is the 52-week range for Quince Therapeutics?

Over the past 52 weeks, Quince Therapeutics has traded between $0.80 and $45.50.

How much debt does Quince Therapeutics have?

As of the most recent reporting period, Quince Therapeutics reported total debt of $18.47M.

How much cash does Quince Therapeutics have on hand?

Quince Therapeutics reported $5.81M in cash and cash equivalents in its most recent financial results.

What is Quince Therapeutics’s dividend yield?

Quince Therapeutics does not currently have a dividend yield.

Quince Therapeutics

Quince Therapeutics Financials at a Glance

QNCX News

Why Cortexyme's Stock Is Crashing Today

2 Short-Squeeze Candidates That Could Go Parabolic Soon

Down 76%: Is Cortexyme Stock a Bargain?

Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors

Here's Why Cortexyme Is Imploding on Wednesday

Is This Under-the-Radar Stock Set to Succeed in Alzheimer's Disease?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Quince Therapeutics

QNCX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Quince Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About QNCX

What is the current price of Quince Therapeutics?

What is the 52-week range for Quince Therapeutics?

How much debt does Quince Therapeutics have?

How much cash does Quince Therapeutics have on hand?

What is Quince Therapeutics’s dividend yield?

Premium Investing Services